Cancer Chemotherapy and Pharmacology

, Volume 63, Issue 1, pp 181–188 | Cite as

Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors

  • Wells A. Messersmith
  • Antonio Jimeno
  • David Ettinger
  • Dan Laheru
  • Julie Brahmer
  • Dina Lansey
  • Yasmin Khan
  • Ross C. Donehower
  • Yusri Elsayed
  • Peter Zannikos
  • Manuel Hidalgo
Clinical Trial Report

Abstract

Purpose

To determine the maximum tolerated dose (MTD) of trabectedin plus gemcitabine administered on a weekly schedule in patients with advanced solid tumors.

Methods

Patients with ECOG performance status 0–1 and adequate organ function were enrolled. On days 1, 8, and 15 of a 28-day cycle, patients received gemcitabine (starting dose, 800 mg/m2) followed by trabectedin (starting dose, 0.3 mg/m2). Strict liver function test treatment criteria were employed to avoid hepatic toxicity seen in previous trabectedin studies. Plasma samples were collected during cycles 1 and 2 for pharmacokinetic analyses.

Results

Fifteen patients received ≥1 dose, with a median of two treatment cycles (range 1–10). The most common drug-related toxicity was hepatic. Dose reductions were required for trabectedin in four (27%) patients and gemcitabine in six (40%) patients. Cycle delays/dose holds were required in 11 (73%) patients and doses above trabectedin 0.4 mg/m2 and gemcitabine 1,000 mg/m2, which is the recommended phase II dose, were not feasible. Seven patients maintained stable disease after two cycles. Gemcitabine and trabectedin pharmacokinetics were not altered substantially with concomitant administration.

Conclusions

Given the lack of pharmacokinetic interaction and potential efficacy of trabectedin and gemcitabine combination therapy, further study is warranted with alternate schedules.

Keywords

Dose-finding Phase I Gemcitabine Pharmacokinetics Trabectedin 

Notes

Acknowledgments

This clinical trial (Study ET-743-USA-7) was sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, NJ and PharmaMar S.A.U., Madrid, Spain. We would like to thank Tom Verhaeghe for overseeing the bioanalysis of trabectedin and gemcitabine. We would also like to thank Lisa Shannon, PharmD, of Scientific Connexions, for providing medical co-writing and editing services.

References

  1. 1.
    Blay JY, von Mehren M, Samuels BL et al (2007) Combination of trabectedin (T) and doxorubicin (D) for the treatment of patients with soft tissue sarcoma (STS): safety and efficacy analysis. J Clin Oncol 25:18s. (Abstr 10078)CrossRefGoogle Scholar
  2. 2.
    Chu QSC, Schwartz G, Forouzesh B et al (2004) Phase I and pharmacokinetic (PK) study of trabectedin (ET-743) administered as a 1-hour infusion weekly for 3 consecutive weeks every 4 weeks to patients with advanced cancer. Presented at the 2004 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 28 September–1 October, Geneva, SwitzerlandGoogle Scholar
  3. 3.
    Cohen RB, Schilder RJ, Cheng J et al (2005) Final results of a combination study between trabectedin and pegylated liposomal doxorubicin (PLD) in patients with advanced malignancies. J Clin Oncol 23:16s. (Abstract 3074)CrossRefGoogle Scholar
  4. 4.
    Damia G, Silvestri S, Carrassa L et al (2001) Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 92:583–588PubMedCrossRefGoogle Scholar
  5. 5.
    Donald S, Verschoyle RD, Greaves P et al (2003) Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug Yondelis (ET-743) in the rat. Cancer Res 63:5902–5908PubMedGoogle Scholar
  6. 6.
    Fetterly GJ, Owen JS, Stuychens K et al (2007) Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectidin (ET-743) treatment. Cancer Chemother Phamacol, 9 October (Epub ahead of print)Google Scholar
  7. 7.
    Garcia-Carbonero R, Supko JG, Maki RG et al (2005) Ecteinascidin-743 for chemotherapy-naïve patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 23:5484–5492PubMedCrossRefGoogle Scholar
  8. 8.
    Garcia-Carbonero R, Supko JG, Manola J et al (2004) Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 22:1480–1490PubMedCrossRefGoogle Scholar
  9. 9.
    Gore L, Rivera E, LaVallee K et al (2006) Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies. J Clin Oncol 24:18s. (Abstract 2079)CrossRefGoogle Scholar
  10. 10.
    Grosso F, Jones RL, Demetri GD et al (2007) Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 8:595–602PubMedCrossRefGoogle Scholar
  11. 11.
    Gurtler JS, Goldstein L, Delprete S et al (2005) Trabectedin in third line breast cancer: a multicenter, randomized, phase II study comparing two administration regimens. J Clin Oncol 23:16s. (Abstract 625)Google Scholar
  12. 12.
    Hendriks HR, Fiebig HH, Giavazzi R et al (1999) High antitumor activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol 10:1233–1240PubMedCrossRefGoogle Scholar
  13. 13.
    Hensley ML, Maki R, Venkatraman E et al (2002) Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 20:2824–2831PubMedCrossRefGoogle Scholar
  14. 14.
    Izbicka E, Lawrence R, Raymond E et al (1998) In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 9:981–987PubMedCrossRefGoogle Scholar
  15. 15.
    Karacetin D, Incekara O (2006) Gemcitabine-cisplatin given on day 1 every 3 weeks in advanced non-small cell lung cancer. J BUON 11:181–184PubMedGoogle Scholar
  16. 16.
    Laverdiere C, Kolb EA, Supko JG et al (2003) Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 98:832–840PubMedCrossRefGoogle Scholar
  17. 17.
    Le Cesne A, Blay JY, Judson I et al (2005) Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group Trial. J Clin Oncol 23:576–584PubMedCrossRefGoogle Scholar
  18. 18.
    Li WW, Takahashi N, Jhanwar S et al (2001) Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 7:2908–2911PubMedGoogle Scholar
  19. 19.
    Look KY, Sandler A, Blessing JA et al (2004) Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol 92:644–647PubMedCrossRefGoogle Scholar
  20. 20.
    Maki RG, Wathen JK, Patel SR et al (2007) Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through study 002. J Clin Oncol 25:2755–2763PubMedCrossRefGoogle Scholar
  21. 21.
    McMeekin DS, Krasner C, Chan S et al (2005) Final results of a phase II study of weekly trabectedin in second/third line ovarian carcinoma. J Clin Oncol 23:16s. (Abstract 5011)Google Scholar
  22. 22.
    Meco D, Colombo T, Ubezio P et al (2003) Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol 52:131–138PubMedCrossRefGoogle Scholar
  23. 23.
    Merimsky O, Meller I, Flusser G et al (2000) Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II trial. Cancer Chemother Pharmacol 45:177–181PubMedCrossRefGoogle Scholar
  24. 24.
    Minuzzo M, Marchini S, Broggini M et al (2000) Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci 97:6780–6784PubMedCrossRefGoogle Scholar
  25. 25.
    Moore BM, Seaman FC, Wheelhouse RT et al (1998) Mechanism for the catalytic activation of ecteinascidin 743 and its subsequent alkylation of guanine N2. J Am Chem Soc 120:2490–2491CrossRefGoogle Scholar
  26. 26.
    Morgan JA, Le Cesne A, Chawla S et al (2007) Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma(L-sarcomas) after failure of prior anthracyclines (A) and ifosfamide (I). J Clin Oncol 25:18s. (Abstract 10060)Google Scholar
  27. 27.
    Pommier Y, Kohlhagen G, Bailly C et al (1996) DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35:13303–13309PubMedCrossRefGoogle Scholar
  28. 28.
    Puchalski TA, Ryan DP, Garcia-Carbonero R et al (2002) Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 50:309–319PubMedCrossRefGoogle Scholar
  29. 29.
    Scotlandi K, Perdichizzi S, Manara MC et al (2002) Effectiveness of ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clin Cancer Res 8:3893–3903PubMedGoogle Scholar
  30. 30.
    Sessa C, DeBraud F, Perotti A et al (2005) Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 23:1867–1874PubMedCrossRefGoogle Scholar
  31. 31.
    Spiridonidis CH, Laufman LR, Jones J et al (1998) Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies. J Clin Oncol 16:3866–3873PubMedGoogle Scholar
  32. 32.
    Sun W, Stevenson JP, Gallagher M et al (2001) A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors. Cancer 92:414–419PubMedCrossRefGoogle Scholar
  33. 33.
    Takahashi N, Li WW, Banerjee D et al (2001) Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 7:3251–3257PubMedGoogle Scholar
  34. 34.
    Takahashi N, Li WW, Banerjee D et al (2002) Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. Cancer Res 62:6909–6915PubMedGoogle Scholar
  35. 35.
    Takebayashi Y, Pourquier P, Zimonjic DB et al (2001) Antiproliferative acitivty of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 7:961–966PubMedCrossRefGoogle Scholar
  36. 36.
    Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216PubMedCrossRefGoogle Scholar
  37. 37.
    Valoti G, Nicoletti MI, Pellegrino A et al (1998) Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res 4:1977–1983PubMedGoogle Scholar
  38. 38.
    Villalona-Calero MA, Eckhardt SG, Weiss G et al (2002) A phase I and pharmacokinetic study of ecteinascidin-743 on a daily ×5 schedule in patients with solid malignancies. Clin Cancer Res 8:75–85PubMedGoogle Scholar
  39. 39.
    Yovine A, Riofrio M, Blay JY et al (2004) Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 22:890–899PubMedCrossRefGoogle Scholar
  40. 40.
    Zelek L, Yovine A, Brain E et al (2006) A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 94:1610–1614PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Wells A. Messersmith
    • 1
  • Antonio Jimeno
    • 2
  • David Ettinger
    • 2
  • Dan Laheru
    • 2
  • Julie Brahmer
    • 2
  • Dina Lansey
    • 2
  • Yasmin Khan
    • 2
  • Ross C. Donehower
    • 2
  • Yusri Elsayed
    • 3
  • Peter Zannikos
    • 3
  • Manuel Hidalgo
    • 2
  1. 1.University of Colorado Cancer CenterAuroraUSA
  2. 2.Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreUSA
  3. 3.Johnson & Johnson Pharmaceutical Research & Development, L.L.C.RaritanUSA

Personalised recommendations